Telesis Bio (NASDAQ:TBIO) Trading Up 3.8%

Telesis Bio, Inc. (NASDAQ:TBIO)’s share price shot up 3.8% during trading on Wednesday . The company traded as high as $3.65 and last traded at $3.55. 38,792 shares traded hands during trading, a decline of 44% from the average session volume of 69,442 shares. The stock had previously closed at $3.42.

Telesis Bio Price Performance

The company has a debt-to-equity ratio of 22.76, a current ratio of 1.89 and a quick ratio of 1.72. The stock has a 50 day simple moving average of $3.80 and a two-hundred day simple moving average of $5.51. The company has a market cap of $5.97 million, a price-to-earnings ratio of -0.13 and a beta of 1.73.

Telesis Bio (NASDAQ:TBIO) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($7.03) EPS for the quarter. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $6.50 million. Telesis Bio had a negative net margin of 282.58% and a negative return on equity of 359.32%.

Telesis Bio Company Profile

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.